Morgan Stanley’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Morgan Stanley’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13	Closed	-$279	–	8095
2024 Q1	$279	Buy	+13	New	+$86	﹤0.01%	7283
2023 Q1	–	Sell	-77	Closed	-$384	–	7885
2022 Q4	$384	Sell	77 -788	-91%	-$3.02K	﹤0.01%	7587
2022 Q3	$5K	Sell	865 -100	-10%	-$868	﹤0.01%	7275
2022 Q2	$8K	Buy	965 +239	+33%	+$2.17K	﹤0.01%	7297
2022 Q1	$11K	Sell	726 -14,652	-95%	-$373K	﹤0.01%	7388
2021 Q4	$738K	Buy	15,378 +15,204	+8,738%	+$1.6M	﹤0.01%	5293
2021 Q3	$26K	Sell	174 -517	-75%	-$67.1K	﹤0.01%	6999
2021 Q2	$81K	Buy	691 +643	+1,340%	+$71.7K	﹤0.01%	6443
2021 Q1	$5K	Buy	+48	New	+$6.26K	﹤0.01%	7126

Morgan Stanley's LABP Position: Q2 2024 in Review

Morgan Stanley sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 13 shares — an estimated $279 sold.

Morgan Stanley first reported a position in LABP in Q1 2021 and held it in 9 quarters. The position peaked at $738K in Q4 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.

Morgan Stanley reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Morgan Stanley sold 13 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $279.
Morgan Stanley first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Morgan Stanley's Landos Biopharma, Inc. Common Stock position peaked at $738K in Q4 2021.
0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.